Internal Medicine, Medical Oncology · Sewell, NJ
NPI
1306007505
Since 2008
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
900 Medical Center Dr Ste 201
Sewell, NJ, 08080
Phone (856) 577-7900
Groups this clinician bills Medicare through
Medicare paid, 2024
$28K
247 services
Medicare patients, 2024
89
Average age 74
Drug cost, 2024
$3.5M
476 prescriptions
Company payments, 2025
$3,436
From 7 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Neil D Palmisiano was code 99215 (office e&m - established), 83 times for 37 patients. In total Neil D Palmisiano billed 247 services in 12 codes, and Medicare paid $28K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-09-11.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Office | 83 | 37 | $149.21 | $12K |
| 99233 Hospital E&M - Subsequent | Facility | 65 | 22 | $99.85 | $6,490 |
| 99223 Hospital E&M - Initial | Facility | 26 | 24 | $145.75 | $3,789 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 21 | 14 | $13.98 | $294 |
| 99215 Office E&M - Established | Facility | 16 | 14 | $94.93 | $1,519 |
By year: 2022 $18K for 182 services; 2023 $30K for 267 services; 2024 $28K for 247 services.
Medicare prescription drug claims, 2024
In 2024, the drug Neil D Palmisiano prescribed most often to Medicare patients was Azacitidine, with 61 prescriptions and refills. In total Neil D Palmisiano wrote 476 Medicare prescriptions that cost $3.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Azacitidine Generic | 61 | 61 | Under 11 | $7,005 |
| Venclexta Venetoclax | 60 | 60 | 15 | $288K |
| Sprycel Dasatinib | 37 | 37 | Under 11 | $524K |
| Inqovi Decitabine/Cedazuridine | 27 | 27 | Under 11 | $219K |
| Tasigna Nilotinib Hcl | 27 | 27 | Under 11 | $523K |
| Xospata Gilteritinib Fumarate | 25 | 27 | Under 11 | $582K |
| Imatinib Mesylate Generic | 22 | 26 | Under 11 | $3,427 |
| Acyclovir Generic | 21 | 22 | 13 | $289 |
| Decitabine Generic | 16 | 16 | Under 11 | $943 |
| Onureg Azacitidine | 14 | 14 | Under 11 | $318K |
| Posaconazole Generic | 12 | 12 | Under 11 | $18K |
| Bosulif Bosutinib | 12 | 12 | Under 11 | $194K |
Brand drugs: 253 claims; generic drugs: 223 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Neil D Palmisiano $3,436 ($2,966 in general payments such as food, travel and fees and $470 for research) from 7 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $1,640.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.